To learn about support groups, services, and publications for people with
Alzheimer's disease, contact the following: Eldercare Locator 1-800-677-1116 Alzheimer's Association 919 North Michigan Avenue Suite 1000 Chicago, Illinois 60611 1-800-272-3900
Alzheimer's Disease Education and Referral (ADEAR) Center P.O.
The Geriatric Health, Education and Research Center consists of 1) the Rehabilitation Research and Training Center on Aging, 2) the Clinical Gerontology Service, 3) the Independent Living Services Program, 4) the Southern California
Alzheimer's Disease Diagnostic and Treatment Center and 5) the Rancho Family Resource Center.
BioArctic AB (STO:BIOAB), a Swedish research-based biopharmaceutical company, announced on Thursday that Eisai has on, 7 march 2019, announced the timelines for the single confirmatory phase 3 study with BAN2401 in early
Alzheimer's disease patients ie mild cognitive impairment due to
Alzheimer's disease or mild
Alzheimer's disease.
Let me share some relevant information and recent research studies about
Alzheimer's disease taken from Internet reports:
"Since the number of cases of both
Alzheimer's disease and cancer increase exponentially as people age, understanding the mechanisms behind this relationship may help us better develop new treatments for both diseases," said study author Massimo Musicco, MD, of the National Research Council of Italy in Milan.
Eleven participants reported having a mother with
Alzheimer's disease, 10 had a father with
Alzheimer's disease and 32 had no history of the disease in their family.
Early diagnosis of
Alzheimer's disease is an important first step in management.
(Nasdaq: SAVA), a clinical-stage biotechnology company, announced today that Remi Barbier, its President and CEO, will present at Maxim Group's conference on
Alzheimer's disease on Wednesday, June 26th, in New York.
Locally,
Alzheimer's disease affects 11.5 per cent of Medicare beneficiaries in Palm Beach County and 12.7 per cent of Medicare beneficiaries in Broward County (a nearly 18 per cent increase over the national average).
BioArctic AB (STO:BIOAB), a Swedish research-based biopharmaceutical company, announced on Friday the initiation by its partner Eisai of the global phase 3 confirmatory study of BAN2401 in patients with early
Alzheimer's disease.
The company added that Eisai and BioArctic remain dedicated to the Alzheimer's community and continue preparations for the confirmatory phase 3 study of BAN2401 in early
Alzheimer's disease.
A comprehensive review of the clinical trial landscape, including current agents being studied for the prevention and treatment of
Alzheimer's disease (and other dementias), points to the need to develop and test drugs based on an understanding of the multiple effects of aging on the brain.